NDAINJECTIONINJECTABLE
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CORVERT (ibutilide fumarate) by Pfizer is mechanism of action: corvert injection prolongs action potential duration in isolated adult cardiac myocytes and increases both atrial and ventricular refractoriness in vivo , ie, class iii electrophysiologic effects. Approved for atrial fibrillation. First approved in 1995.
Drug data last refreshed 20h ago
Mechanism of Action
Mechanism of Action: CORVERT Injection prolongs action potential duration in isolated adult cardiac myocytes and increases both atrial and ventricular refractoriness in vivo , ie, class III electrophysiologic effects. Voltage clamp studies indicate that CORVERT, at nanomolar concentrations, delays…
Indications (1)
Company
Worked on CORVERT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.